|
|
|
Volumn 22, Issue 135, 2013, Pages 36-37
|
|
Linagliptin. Avoid gliptins!
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
GLYCOSYLATED HEMOGLOBIN;
HEMOGLOBIN A1C PROTEIN, HUMAN;
LINAGLIPTIN;
PURINE DERIVATIVE;
QUINAZOLINE DERIVATIVE;
BLOOD;
CHEMICALLY INDUCED DISORDER;
DIABETES MELLITUS;
DRUG COMBINATION;
DRUG EFFECT;
DRUG HYPERSENSITIVITY;
DRUG INTERACTION;
HUMAN;
IMMUNE SYSTEM;
METABOLISM;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PANCREATITIS;
PATIENT SELECTION;
REVIEW;
RISK ASSESSMENT;
RISK FACTOR;
TREATMENT OUTCOME;
BIOLOGICAL MARKERS;
DIABETES COMPLICATIONS;
DIABETES MELLITUS, TYPE 2;
DIPEPTIDYL-PEPTIDASE IV INHIBITORS;
DRUG HYPERSENSITIVITY;
DRUG INTERACTIONS;
DRUG THERAPY, COMBINATION;
HEMOGLOBIN A, GLYCOSYLATED;
HUMANS;
IMMUNE SYSTEM;
PANCREATITIS;
PATIENT SELECTION;
PURINES;
QUINAZOLINES;
RISK ASSESSMENT;
RISK FACTORS;
TREATMENT OUTCOME;
|
|
EID: 84875002420
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (3)
|
|
References (0)
|